Covidien restructuring
This article was originally published in The Gray Sheet
Executive Summary
Firm anticipates annual savings of $50 million-$75 million from a company-wide restructuring program impacting its medical devices, imaging solutions, pharmaceutical products and medical supplies units. The Bermuda conglomerate says the program will start this quarter and cost $200 million